To further improve the efficacy of this multi-epitope vaccine, a recently discovered neo-antigen (Rpl18), the main driver for endogenous CD8+ T-cell response in the MC-38 colon adenocarcinoma [14], was included in a newly designed KISIMA construct (KISIMA-Mad46 comprising Adpgk-, Reps1- and Rpl18-derived epitopes) as well as into the VSV-GP backbone (VSV-GP-Mad46). Here, RPL18 is linked to colon adenocarcinoma.